Apr 08, 2020
Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)
Dec 12, 2019
Nordic Nanovector Provides Update on LYMRIT 37-05 Phase 1 DLBCL Trial
Jul 11, 2019
Nordic Nanovector Completes Patient Enrolment Into Phase 1 Trial of Betalutin® in Diffuse Large B-cell Lymphoma (DLBCL)
Jun 14, 2019
Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures
May 22, 2019
Genomic Testing Cooperative (GTC) and Collaborators to Present Data Resulting from its Proprietary DNA and RNA Profiling of Diffuse Large B-cell Lymphoma at the 2019 ASCO Annual Meeting
May 20, 2019
Three DB102 (Enzastaurin) Presentations at ASCO and the 15th International Conference on Malignant Lymphoma (ICML)
Dec 03, 2018
Kymera Therapeutics Presents First Validation of IRAK4 Protein Degraders in MYD88-Mutant Lymphoma
Nov 26, 2018
Two Posters on DB102 (Enzastaurin) Presented at the American Society of Hematology Annual Meeting
Jun 16, 2018
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
May 03, 2018
Forty Seven, Inc. Granted Fast Track Designation for 5F9 for the Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Apr 03, 2018
First Patient Dosed In Pivotal Biomarker-Guided Phase 3 Study Of First Line Therapy With DB102 (enzastaurin) + R-CHOP In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)
Mar 16, 2018
Diffuse Large B Cell Lymphoma Drug Market, 2024 - 84 Drugs in the Clinical Pipeline